By Marion Munywoki
The Pharmacy and Poisons Board (PPB)-the national drug regulator- has warned all healthcare practitioners and members of the public to stop the circulation of Tamedol oral solution over quality concerns.
According to PPB CEO Dr. Fred Siyoi, PPB have received multiple market complaints on the quality of several batches of Tamedol oral solution (Paracetamol oral solution, 120mg/5ml, 60 mls) manufactured by Biopharma LTD, Kenya.
Tamedol is widely used for headaches, colds and influenza, backache, period pain, the pain of osteoarthritis, muscle pain, toothache, and rheumatic pain.
This is as a result of investigations that confirmed the product failed to meet the market authorization requirement. That has initiated mandatory recall of the product by the manufacturer in line with Section 3A) of the Pharmacy and Poisons Act (Cap. 244).
Consequently, the board has advised the quarantine of the product, medical health providers have been advised to stop prescribing the Tamedol oral solution and return the products to the respective suppliers.
The Pharmacy and poisons Board has assured the public that measures to ensure medicines supplied are of quality standard ensuring safety and efficiency.
“We encourage the public to remain vigilant at all times and promptly report any suspected cases of sub-standard medicines or adverse drug reactions to the nearest healthcare facility or the Pharmacy and Poisons Board.”
